Loading...

Invitae

DB:IV8
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IV8
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Invitae has significant price volatility in the past 3 months.
IV8 Share Price and Events
7 Day Returns
-15.5%
DB:IV8
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
332.6%
DB:IV8
-10.2%
DE Biotechs
-6%
DE Market
IV8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Invitae (IV8) -15.5% -11.4% 52.4% 332.6% 112.4% -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • IV8 outperformed the Biotechs industry which returned -10.2% over the past year.
  • IV8 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
IV8
Industry
5yr Volatility vs Market

Value

 Is Invitae undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Invitae. This is due to cash flow or dividend data being unavailable. The share price is €19.684.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Invitae's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Invitae's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IV8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.94
NYSE:NVTA Share Price ** NYSE (2019-04-18) in USD $22.79
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Invitae.

DB:IV8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:NVTA Share Price ÷ EPS (both in USD)

= 22.79 ÷ -1.94

-11.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitae is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Invitae is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Invitae's expected growth come at a high price?
Raw Data
DB:IV8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
40.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Invitae, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Invitae's assets?
Raw Data
DB:IV8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.14
NYSE:NVTA Share Price * NYSE (2019-04-18) in USD $22.79
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:IV8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:NVTA Share Price ÷ Book Value per Share (both in USD)

= 22.79 ÷ 2.14

10.63x

* Primary Listing of Invitae.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Invitae is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Invitae's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Invitae has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Invitae expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Invitae expected to grow at an attractive rate?
  • Invitae's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Invitae's earnings growth is expected to exceed the Germany market average.
  • Invitae's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IV8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IV8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 40.5%
DB:IV8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 26.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IV8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IV8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 678 29 1
2022-12-31 538 -28 1
2021-12-31 437 39 -43 5
2020-12-31 325 -92 -93 8
2019-12-31 224 -110 -144 8
DB:IV8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 148 -92 -129
2018-09-30 128 -108 -140
2018-06-30 109 -115 -136
2018-03-31 86 -109 -133
2017-12-31 68 -98 -123
2017-09-30 52 -84 -108
2017-06-30 40 -76 -105
2017-03-31 31 -74 -102
2016-12-31 25 -76 -100
2016-09-30 19 -80 -100
2016-06-30 15 -85 -97
2016-03-31 11 -86 -97

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Invitae's earnings are expected to grow significantly at over 20% yearly.
  • Invitae's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IV8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IV8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.30 0.30 0.30 1.00
2022-12-31 -0.29 -0.29 -0.29 1.00
2021-12-31 -0.48 -0.17 -0.81 5.00
2020-12-31 -1.14 -0.80 -1.56 7.00
2019-12-31 -1.72 -1.56 -1.93 7.00
DB:IV8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.94
2018-09-30 -2.30
2018-06-30 -2.45
2018-03-31 -2.68
2017-12-31 -2.65
2017-09-30 -2.53
2017-06-30 -2.73
2017-03-31 -2.84
2016-12-31 -3.02
2016-09-30 -3.11
2016-06-30 -3.04
2016-03-31 -3.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Invitae will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Invitae's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Invitae has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Invitae performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Invitae's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Invitae does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Invitae's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Invitae's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Invitae's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Invitae Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IV8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 147.70 -129.36 122.51 63.50
2018-09-30 127.74 -140.01 116.90 60.53
2018-06-30 108.52 -135.69 111.70 56.26
2018-03-31 85.55 -132.57 101.28 51.81
2017-12-31 68.22 -123.38 91.29 46.47
2017-09-30 52.06 -107.74 77.39 44.64
2017-06-30 40.19 -105.30 65.10 44.62
2017-03-31 31.43 -101.59 57.29 43.99
2016-12-31 25.05 -100.26 51.72 44.63
2016-09-30 18.97 -99.77 48.15 44.24
2016-06-30 14.88 -97.32 45.25 43.89
2016-03-31 11.10 -96.74 42.94 45.01
2015-12-31 8.38 -89.78 38.53 42.81
2015-09-30 6.09 -80.73 35.29 37.89
2015-06-30 4.22 -70.82 31.34 32.31
2015-03-31 2.72 -57.10 25.89 25.55
2014-12-31 1.60 -47.49 21.27 22.06
2014-09-30 0.82 -40.32 16.49 21.02
2014-06-30 0.56 -34.75 13.31 19.92
2014-03-31 0.26 -29.12 10.14 17.92
2013-12-31 0.15 -24.99 8.20 16.04
2012-12-31 -9.01 3.00 5.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Invitae has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Invitae has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Invitae improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Invitae's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Invitae has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Invitae's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Invitae's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Invitae is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Invitae's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Invitae's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Invitae Company Filings, last reported 3 months ago.

DB:IV8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 161.84 77.79 125.89
2018-09-30 179.40 62.27 129.18
2018-06-30 138.65 62.88 85.14
2018-03-31 101.96 63.33 54.97
2017-12-31 121.79 44.50 64.66
2017-09-30 125.39 43.30 76.91
2017-06-30 67.16 42.97 75.37
2017-03-31 82.30 41.73 96.78
2016-12-31 99.07 13.68 92.62
2016-09-30 70.84 14.92 66.75
2016-06-30 92.69 13.49 85.29
2016-03-31 114.51 11.91 103.87
2015-12-31 138.38 10.20 127.02
2015-09-30 161.10 8.43 147.25
2015-06-30 182.65 4.13 170.93
2015-03-31 206.36 3.21 184.33
2014-12-31 118.73 3.54 107.03
2014-09-30 65.14 1.38 59.14
2014-06-30 30.19 1.60 22.04
2014-03-31 49.29 2.00 43.07
2013-12-31 49.29 2.00 43.07
2012-12-31 24.00 1.22 21.80
  • Invitae's level of debt (48.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (4.1% vs 48.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Invitae has sufficient cash runway for 1.3 years based on current free cash flow.
  • Invitae has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 9.4% each year.
X
Financial health checks
We assess Invitae's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Invitae has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Invitae's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Invitae dividends.
If you bought €2,000 of Invitae shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Invitae's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Invitae's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IV8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IV8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Invitae has not reported any payouts.
  • Unable to verify if Invitae's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Invitae's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Invitae has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Invitae's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Invitae afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Invitae has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Invitae's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sean George
COMPENSATION $3,563,844
AGE 44
TENURE AS CEO 2.3 years
CEO Bio

Dr. Sean E. George, Ph.D. is the Co-Founder of InVitae Corporation and has been its President since August 2012. Dr. George has been Chief Executive Officer of InVitae Corporation since January 9, 2017 and served as its Chief Operating Officer since August 2008 until January 9, 2017. He has held a number of executive management positions in the life science industry. He served as Chief Operating Officer of Navigenics, Inc. since 2007 until November 2009. He was Co-Founder and Chief Executive Officer of Locus Development Inc. Dr. George served as the President at Locus Development Inc. Dr. George served at Affymetrix, Inc., as Senior Vice President of Marketing, responsible for its marketing, corporate communications, product management, and CRM divisions. He served as Senior Vice President, Life Science Business at Affymetrix. Dr. George served as vice president of life science research at Affymetrix. Dr. George served at Invitrogen, Inc., as vice president of diagnostic solutions, managing its anatomical pathology diagnostic business and driving business to diagnostic and other tools companies. He served as Vice President, Labeling and Detection Business at Invitrogen. Dr. George was strategic planning director of Molecular Probes. Dr. George served as an associate at McKinsey & Company, where he served with various clients in the pharmaceutical and biotech and corporate finance practices. He has been a Director of InVitae Corporation since January 2010. He serves as Member of Scientific advisory board at Genia Technologies, Inc. (alternate name, Genia Corporation). He served as Director at Locus Development Inc. Dr. George received his B.S. in microbiology and molecular genetics from the University of California, Los Angeles, his M.S. in molecular biology from the University of California, Santa Barbara and his Ph.D. in molecular genetics from the University of California, Santa Cruz.

CEO Compensation
  • Sean's compensation has increased whilst company is loss making.
  • Sean's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Invitae management team in years:

2.3
Average Tenure
58
Average Age
  • The tenure for the Invitae management team is about average.
Management Team

Randy Scott

TITLE
Executive Chairman
COMPENSATION
$322K
AGE
60
TENURE
2.3 yrs

Sean George

TITLE
Co-Founder
COMPENSATION
$4M
AGE
44
TENURE
2.3 yrs

Shelly Guyer

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
58
TENURE
1.8 yrs

Lee Bendekgey

TITLE
Secretary & COO
COMPENSATION
$916K
AGE
60
TENURE
1.8 yrs

Laura D'Angelo

TITLE
Head of Investor Relations

Tom Brida

TITLE
General Counsel
AGE
47
TENURE
2.3 yrs

Robert Nussbaum

TITLE
Chief Medical Officer
COMPENSATION
$803K
AGE
68
TENURE
3.7 yrs

Katherine Stueland

TITLE
Chief Commercial Officer
AGE
42
TENURE
2.5 yrs

Eric Olivares

TITLE
Head of Clinical Operations & Assay Development
TENURE
2.2 yrs

Alex Furman

TITLE
Executive Officer of Organizational Development
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Invitae board of directors in years:

6.9
Average Tenure
56
Average Age
  • The tenure for the Invitae board of directors is about average.
Board of Directors

Randy Scott

TITLE
Executive Chairman
COMPENSATION
$322K
AGE
60
TENURE
6.7 yrs

Sean George

TITLE
Co-Founder
COMPENSATION
$4M
AGE
44
TENURE
9.3 yrs

Eric Aguiar

TITLE
Independent Director
COMPENSATION
$122K
AGE
56
TENURE
8.6 yrs

Christine Gorjanc

TITLE
Independent Director
COMPENSATION
$117K
AGE
61
TENURE
3.4 yrs

Geoff Crouse

TITLE
Independent Director
COMPENSATION
$122K
AGE
47
TENURE
7.1 yrs

Elizabeth McNally

TITLE
Member of Advisory Board

Chitra Nayak

TITLE
Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • Invitae insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Apr 19 Sell Katherine Stueland Individual 16. Apr 19 16. Apr 19 -1,000 €22.35 €-22,346
29. Nov 18 Sell Eric Aguiar Individual 27. Nov 18 27. Nov 18 -10,000 €11.95 €-119,543
20. Sep 18 Sell Patricia Dumond Individual 18. Sep 18 20. Sep 18 -645 €14.19 €-9,103
12. Sep 18 Sell Katherine Stueland Individual 09. Sep 18 09. Sep 18 -595 €11.76 €-6,999
17. May 18 Sell Patricia Dumond Individual 15. May 18 15. May 18 -5,014 €5.87 €-29,412
17. May 18 Sell Sean George Individual 15. May 18 15. May 18 -20,311 €5.87 €-119,142
17. May 18 Sell Robert Nussbaum Individual 15. May 18 15. May 18 -6,702 €5.87 €-39,313
17. May 18 Sell Lee Bendekgey Individual 15. May 18 15. May 18 -6,388 €5.87 €-37,471
17. May 18 Sell Thomas Brida Individual 15. May 18 15. May 18 -1,979 €5.87 €-11,609
17. May 18 Sell Katherine Stueland Individual 15. May 18 15. May 18 -6,012 €5.87 €-35,266
17. May 18 Sell Shelly Guyer Individual 15. May 18 15. May 18 -5,135 €5.87 €-30,121
X
Management checks
We assess Invitae's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Invitae has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. The company also operates AltaVoice, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform for collecting and managing genetic family histories to deliver personalized genetic risk information. It serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.

Details
Name: Invitae Corporation
IV8
Exchange: DB
Founded: 2010
$1,768,201,982
87,161,562
Website: http://www.invitae.com
Address: Invitae Corporation
1400 16th Street,
San Francisco,
California, 94103,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE NVTA Common Stock New York Stock Exchange US USD 12. Feb 2015
DB IV8 Common Stock Deutsche Boerse AG DE EUR 12. Feb 2015
LSE 0JDB Common Stock London Stock Exchange GB USD 12. Feb 2015
Number of employees
Current staff
Staff numbers
788
Invitae employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:18
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.